APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pramipexole Hydrochloride Extended Release Tablets

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pramipexole Hydrochloride Extended Release Tablets Market Outlook and Growth Opportunities 2026

29 December 2025192 pages

Choose your research edition.

Industry ResearchPramipexole Hydrochloride Extended Release Tablets Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Pramipexole Hydrochloride Extended Release Tablets Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Pramipexole Hydrochloride Extended Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pramipexole Hydrochloride Extended Release Tablets Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Pramipexole Hydrochloride Extended Release Tablets Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Pramipexole Hydrochloride Extended Release Tablets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pramipexole Hydrochloride Extended Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pramipexole Hydrochloride Extended Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pramipexole Hydrochloride Extended Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pramipexole Hydrochloride Extended Release Tablets market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pramipexole Hydrochloride Extended Release Tablets market include Tianjin Chasesun Pharmaceutical, Qilu Pharmaceutical (Hainan), Zhejiang Jingxin Pharmaceutical, Xiamen LP Pharmaceutical, Macleods Pharmaceuticals Ltd, Cspc Ouyi Pharmaceutical and Boehringer Ingelheim International GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pramipexole Hydrochloride Extended Release Tablets market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pramipexole Hydrochloride Extended Release Tablets and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pramipexole Hydrochloride Extended Release Tablets revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pramipexole Hydrochloride Extended Release Tablets market.

Pramipexole Hydrochloride Extended Release Tablets Segment by Company

Tianjin Chasesun Pharmaceutical

Qilu Pharmaceutical (Hainan)

Zhejiang Jingxin Pharmaceutical

Xiamen LP Pharmaceutical

Macleods Pharmaceuticals Ltd

Cspc Ouyi Pharmaceutical

Boehringer Ingelheim International GmbH

Pramipexole Hydrochloride Extended Release Tablets Segment by Type

0.75mg

1.5mg

3.0mg

4.5mg

Others

Pramipexole Hydrochloride Extended Release Tablets Segment by Application

Hospital

Clinic

Others

Pramipexole Hydrochloride Extended Release Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pramipexole Hydrochloride Extended Release Tablets status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pramipexole Hydrochloride Extended Release Tablets key companies, revenue, market share, and recent developments.

3. To split the Pramipexole Hydrochloride Extended Release Tablets breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pramipexole Hydrochloride Extended Release Tablets market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pramipexole Hydrochloride Extended Release Tablets significant trends, drivers, influence factors in global and regions.

6. To analyze Pramipexole Hydrochloride Extended Release Tablets competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pramipexole Hydrochloride Extended Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pramipexole Hydrochloride Extended Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pramipexole Hydrochloride Extended Release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pramipexole Hydrochloride Extended Release Tablets industry.

Chapter 3: Detailed analysis of Pramipexole Hydrochloride Extended Release Tablets company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pramipexole Hydrochloride Extended Release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pramipexole Hydrochloride Extended Release Tablets in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pramipexole Hydrochloride Extended Release Tablets Industry Trends Table 2. Pramipexole Hydrochloride Extended Release Tablets Industry Drivers Table 3. Pramipexole Hydrochloride Extended Release Tablets Industry Opportunities and Challenges Table 4. Pramipexole Hydrochloride Extended Release Tablets Industry Restraints Table 5. Global Pramipexole Hydrochloride Extended Release Tablets Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pramipexole Hydrochloride Extended Release Tablets Revenue Share by Company (2021-2026) Table 7. Global Pramipexole Hydrochloride Extended Release Tablets Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pramipexole Hydrochloride Extended Release Tablets Key Company Manufacturing Base & Headquarters Table 9. Global Pramipexole Hydrochloride Extended Release Tablets Company, Product Type & Application Table 10. Global Pramipexole Hydrochloride Extended Release Tablets Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pramipexole Hydrochloride Extended Release Tablets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 0.75mg Table 15. Significant Companies of 1.5mg Table 16. Significant Companies of 3.0mg Table 17. Significant Companies of 4.5mg Table 18. Significant Companies of Others Table 19. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type (2021-2026) Table 23. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Table 25. Significant Companies of Clinic Table 26. Significant Companies of Others Table 27. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application (2021-2026) Table 31. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application (2027-2032) Table 32. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Region (2021-2026) Table 35. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Region (2027-2032) Table 37. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Market Share by Country (2021-2026) Table 40. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Market Share by Country (2027-2032) Table 42. Tianjin Chasesun Pharmaceutical Company Information Table 43. Tianjin Chasesun Pharmaceutical Business Overview Table 44. Tianjin Chasesun Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Tianjin Chasesun Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Product Portfolio Table 46. Tianjin Chasesun Pharmaceutical Recent Development Table 47. Qilu Pharmaceutical (Hainan) Company Information Table 48. Qilu Pharmaceutical (Hainan) Business Overview Table 49. Qilu Pharmaceutical (Hainan) Pramipexole Hydrochloride Extended Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Qilu Pharmaceutical (Hainan) Pramipexole Hydrochloride Extended Release Tablets Product Portfolio Table 51. Qilu Pharmaceutical (Hainan) Recent Development Table 52. Zhejiang Jingxin Pharmaceutical Company Information Table 53. Zhejiang Jingxin Pharmaceutical Business Overview Table 54. Zhejiang Jingxin Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Zhejiang Jingxin Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Product Portfolio Table 56. Zhejiang Jingxin Pharmaceutical Recent Development Table 57. Xiamen LP Pharmaceutical Company Information Table 58. Xiamen LP Pharmaceutical Business Overview Table 59. Xiamen LP Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Xiamen LP Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Product Portfolio Table 61. Xiamen LP Pharmaceutical Recent Development Table 62. Macleods Pharmaceuticals Ltd Company Information Table 63. Macleods Pharmaceuticals Ltd Business Overview Table 64. Macleods Pharmaceuticals Ltd Pramipexole Hydrochloride Extended Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Macleods Pharmaceuticals Ltd Pramipexole Hydrochloride Extended Release Tablets Product Portfolio Table 66. Macleods Pharmaceuticals Ltd Recent Development Table 67. Cspc Ouyi Pharmaceutical Company Information Table 68. Cspc Ouyi Pharmaceutical Business Overview Table 69. Cspc Ouyi Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Cspc Ouyi Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Product Portfolio Table 71. Cspc Ouyi Pharmaceutical Recent Development Table 72. Boehringer Ingelheim International GmbH Company Information Table 73. Boehringer Ingelheim International GmbH Business Overview Table 74. Boehringer Ingelheim International GmbH Pramipexole Hydrochloride Extended Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Boehringer Ingelheim International GmbH Pramipexole Hydrochloride Extended Release Tablets Product Portfolio Table 76. Boehringer Ingelheim International GmbH Recent Development Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. Pramipexole Hydrochloride Extended Release Tablets Product Image Figure 2. Global Pramipexole Hydrochloride Extended Release Tablets Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pramipexole Hydrochloride Extended Release Tablets Market Size (2021-2032) & (US$ Million) Figure 4. Global Pramipexole Hydrochloride Extended Release Tablets Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 0.75mg Image Figure 8. 1.5mg Image Figure 9. 3.0mg Image Figure 10. 4.5mg Image Figure 11. Others Image Figure 12. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type (2021-2032) Figure 15. Hospital Image Figure 16. Clinic Image Figure 17. Others Image Figure 18. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application (2021-2032) Figure 21. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Pramipexole Hydrochloride Extended Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 24. North America Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Pramipexole Hydrochloride Extended Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Pramipexole Hydrochloride Extended Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Pramipexole Hydrochloride Extended Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 30. South America Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Pramipexole Hydrochloride Extended Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • 0.75mg
  • 1.5mg
  • 3.0mg
  • 4.5mg
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Tianjin Chasesun Pharmaceutical
  • Qilu Pharmaceutical (Hainan)
  • Zhejiang Jingxin Pharmaceutical
  • Xiamen LP Pharmaceutical
  • Macleods Pharmaceuticals Ltd
  • Cspc Ouyi Pharmaceutical
  • Boehringer Ingelheim International GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pramipexole Hydrochloride Extended Release Tablets Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pramipexole Hydrochloride Extended Release Tablets Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pramipexole Hydrochloride Extended Release Tablets Market Dynamics
  1. 2.1 Pramipexole Hydrochloride Extended Release Tablets Industry Trends
  2. 2.2 Pramipexole Hydrochloride Extended Release Tablets Industry Drivers
  3. 2.3 Pramipexole Hydrochloride Extended Release Tablets Industry Opportunities and Challenges
  4. 2.4 Pramipexole Hydrochloride Extended Release Tablets Industry Restraints
3 Pramipexole Hydrochloride Extended Release Tablets Market by Company
  1. 3.1 Global Pramipexole Hydrochloride Extended Release Tablets Company Revenue Ranking in 2025
  2. 3.2 Global Pramipexole Hydrochloride Extended Release Tablets Revenue by Company (2021-2026)
  3. 3.3 Global Pramipexole Hydrochloride Extended Release Tablets Company Ranking (2024-2026)
  4. 3.4 Global Pramipexole Hydrochloride Extended Release Tablets Company Manufacturing Base and Headquarters
  5. 3.5 Global Pramipexole Hydrochloride Extended Release Tablets Company Product Type and Application
  6. 3.6 Global Pramipexole Hydrochloride Extended Release Tablets Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pramipexole Hydrochloride Extended Release Tablets Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pramipexole Hydrochloride Extended Release Tablets Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pramipexole Hydrochloride Extended Release Tablets Market by Type
  1. 4.1 Pramipexole Hydrochloride Extended Release Tablets Type Introduction
  2. 4.1.1 0.75mg
  3. 4.1.2 1.5mg
  4. 4.1.3 3.0mg
  5. 4.1.4 4.5mg
  6. 4.1.5 Others
  7. 4.2 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Type
  8. 4.2.1 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Type (2021-2032)
  10. 4.2.3 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type (2021-2032)
5 Pramipexole Hydrochloride Extended Release Tablets Market by Application
  1. 5.1 Pramipexole Hydrochloride Extended Release Tablets Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Application
  6. 5.2.1 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Application (2021-2032)
  8. 5.2.3 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application (2021-2032)
6 Pramipexole Hydrochloride Extended Release Tablets Regional Value Analysis
  1. 6.1 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pramipexole Hydrochloride Extended Release Tablets Sales Value (2021-2032)
  7. 6.3.2 North America Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pramipexole Hydrochloride Extended Release Tablets Sales Value (2021-2032)
  10. 6.4.2 Europe Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pramipexole Hydrochloride Extended Release Tablets Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pramipexole Hydrochloride Extended Release Tablets Sales Value (2021-2032)
  16. 6.6.2 South America Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pramipexole Hydrochloride Extended Release Tablets Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Country, 2025 VS 2032
7 Pramipexole Hydrochloride Extended Release Tablets Country-level Value Analysis
  1. 7.1 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pramipexole Hydrochloride Extended Release Tablets Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pramipexole Hydrochloride Extended Release Tablets Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pramipexole Hydrochloride Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Tianjin Chasesun Pharmaceutical
  2. 8.1.1 Tianjin Chasesun Pharmaceutical Company Information
  3. 8.1.2 Tianjin Chasesun Pharmaceutical Business Overview
  4. 8.1.3 Tianjin Chasesun Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Tianjin Chasesun Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Product Portfolio
  6. 8.1.5 Tianjin Chasesun Pharmaceutical Recent Developments
  7. 8.2 Qilu Pharmaceutical (Hainan)
  8. 8.2.1 Qilu Pharmaceutical (Hainan) Company Information
  9. 8.2.2 Qilu Pharmaceutical (Hainan) Business Overview
  10. 8.2.3 Qilu Pharmaceutical (Hainan) Pramipexole Hydrochloride Extended Release Tablets Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Qilu Pharmaceutical (Hainan) Pramipexole Hydrochloride Extended Release Tablets Product Portfolio
  12. 8.2.5 Qilu Pharmaceutical (Hainan) Recent Developments
  13. 8.3 Zhejiang Jingxin Pharmaceutical
  14. 8.3.1 Zhejiang Jingxin Pharmaceutical Company Information
  15. 8.3.2 Zhejiang Jingxin Pharmaceutical Business Overview
  16. 8.3.3 Zhejiang Jingxin Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Zhejiang Jingxin Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Product Portfolio
  18. 8.3.5 Zhejiang Jingxin Pharmaceutical Recent Developments
  19. 8.4 Xiamen LP Pharmaceutical
  20. 8.4.1 Xiamen LP Pharmaceutical Company Information
  21. 8.4.2 Xiamen LP Pharmaceutical Business Overview
  22. 8.4.3 Xiamen LP Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Xiamen LP Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Product Portfolio
  24. 8.4.5 Xiamen LP Pharmaceutical Recent Developments
  25. 8.5 Macleods Pharmaceuticals Ltd
  26. 8.5.1 Macleods Pharmaceuticals Ltd Company Information
  27. 8.5.2 Macleods Pharmaceuticals Ltd Business Overview
  28. 8.5.3 Macleods Pharmaceuticals Ltd Pramipexole Hydrochloride Extended Release Tablets Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Macleods Pharmaceuticals Ltd Pramipexole Hydrochloride Extended Release Tablets Product Portfolio
  30. 8.5.5 Macleods Pharmaceuticals Ltd Recent Developments
  31. 8.6 Cspc Ouyi Pharmaceutical
  32. 8.6.1 Cspc Ouyi Pharmaceutical Company Information
  33. 8.6.2 Cspc Ouyi Pharmaceutical Business Overview
  34. 8.6.3 Cspc Ouyi Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cspc Ouyi Pharmaceutical Pramipexole Hydrochloride Extended Release Tablets Product Portfolio
  36. 8.6.5 Cspc Ouyi Pharmaceutical Recent Developments
  37. 8.7 Boehringer Ingelheim International GmbH
  38. 8.7.1 Boehringer Ingelheim International GmbH Company Information
  39. 8.7.2 Boehringer Ingelheim International GmbH Business Overview
  40. 8.7.3 Boehringer Ingelheim International GmbH Pramipexole Hydrochloride Extended Release Tablets Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Boehringer Ingelheim International GmbH Pramipexole Hydrochloride Extended Release Tablets Product Portfolio
  42. 8.7.5 Boehringer Ingelheim International GmbH Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst